What is the current stock price of Humacyte, Inc. (HUMA)?

As of the latest market data, Humacyte, Inc. (HUMA) is trading at $0.65. The stock has seen a gain of 6.33% today.

Does Humacyte, Inc. (HUMA) pay a dividend?

Based on current data, Humacyte, Inc. does not have a confirmed active dividend policy.

What is the market cap of Humacyte, Inc.?

The current market capitalization of Humacyte, Inc. (HUMA) is approximately unavailable.

HUMA

Humacyte, Inc.·Healthcare

0.65

6.326%(+0.04)

Market Closed

0.70

8.150%(+0.05)

After Hours

Last Updated: — ET

52W L: $0.5552W H: $2.93

HUMA NEWS

prnewswire.com

1d ago

Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

zacks.com

3d ago

Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors

In the latest trading session, Humacyte, Inc. (HUMA) closed at $0.61, marking a -6.63% move from the previous day.

zacks.com

Apr 1

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.59, representing a -2.44% change from its previous close.

seekingalpha.com

Mar 27

Humacyte, Inc. (HUMA) Q4 2025 Earnings Call Transcript

zacks.com

Mar 27

Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.13 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.

globenewswire.com

Mar 27

Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -

Company Profile

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Sector

Healthcare

Industry

Biotechnology

Employees

218

IPO Date

2020-12-01

Beta

2.10

Websitewww.humacyte.com↗